All Stories

  1. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids
  2. Resveratrol modulates pancreatic proteotoxic stress and metabolic dysfunction in human IAPP transgenic mice
  3. Allosteric Modulation of the CB1 Receptor by a Juniper Berry Seasoning Extract: Deoxypodophyllotoxin as the Major Active Constituent
  4. Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy
  5. Development of cannabinoid-based therapies for Parkinson’s disease: emphasis on targeting cannabinoid receptors as CB2, PPAR-γ and GPR55 receptors
  6. Defining the Intestinal eCBome and Oxylipin Signaling Systems in a TDP‐43 Mouse Model of Frontotemporal Dementia
  7. Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB2 receptor activation in experimental ALS in male mice
  8. Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis
  9. Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (−) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives
  10. Neurodegenerative Diseases: Pathogenesis and Preclinical Models for Translational Drug Discovery
  11. Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome
  12. Ageing, Neurodegeneration and the Endocannabinoid System
  13. Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays
  14. Neurodegeneration and the endocannabinoid system: Toward the development of cannabinoid-based therapies for Parkinson's disease, amyotrophic lateral sclerosis and spinocerebellar ataxias
  15. Mouse Models of Amyotrophic Lateral Sclerosis
  16. Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy
  17. Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia
  18. Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche’s Endocannabinoid System Projects
  19. Preclinical Assessment of a Cannabinoid CB2 Receptor Antagonist in a Murine Model of Cerebral Malaria
  20. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice
  21. From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline
  22. Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome
  23. The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
  24. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice
  25. Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure–Activity Relationship
  26. Endocannabinoid-Binding Receptors as Drug Targets
  27. New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
  28. Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome
  29. Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis
  30. BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis
  31. (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice
  32. Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease
  33. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
  34. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis
  35. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease
  36. Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis
  37. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis
  38. Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments
  39. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
  40. Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor**
  41. Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors
  42. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
  43. Possible therapeutic applications of cannabis in the neuropsychopharmacology field
  44. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment
  45. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders
  46. Chapter 2. Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System
  47. Structure–Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives
  48. Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease
  49. Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets
  50. Morphine self-administration alters the expression of translational machinery genes in the amygdala of male Lewis rats
  51. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
  52. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
  53. Preface: Why a Special Issue on cannabinoid research in Spain?
  54. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways
  55. The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes
  56. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
  57. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
  58. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients
  59. Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists
  60. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. 110 (August 2016) (2016) 205–215]
  61. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3
  62. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease
  63. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
  64. Synthesis of a novel CB2 cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione
  65. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies
  66. Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis
  67. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3
  68. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders
  69. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile
  70. Targeting the cannabinoid CB 2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice
  71. VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease
  72. Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis
  73. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
  74. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties
  75. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome
  76. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
  77. Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology
  78. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease
  79. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ-tetrahydrocannabinol acting through CB1 receptors
  80. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications
  81. Altered CB1receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects
  82. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB 2 receptor antagonists
  83. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia
  84. A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis
  85. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders
  86. Selective, Nontoxic CB2Cannabinoido-Quinone with in Vivo Activity against Triple-Negative Breast Cancer
  87. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson’s disease
  88. Endocannabinoids and Neurodegenerative Disorders: Parkinson’s Disease, Huntington’s Chorea, Alzheimer’s Disease, and Others
  89. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice
  90. Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling
  91. The endocannabinoid system is altered in the post‐mortem prefrontal cortex of alcoholic subjects
  92. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
  93. A restricted population of CB 1 cannabinoid receptors with neuroprotective activity
  94. Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1G93ATransgenic Mice and Evaluation of a Sativex®-like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis
  95. Changes in CB1 and CB2 receptors in the post‐mortem cerebellum of humans affected by spinocerebellar ataxias
  96. Compounds combining pharmacophoric elements of CB1 and opioid mu.
  97. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease
  98. Endocannabinoid-Hydrolysing Enzymes in the Post-Mortem Cerebellum of Humans Affected by Hereditary Autosomal Dominant Ataxias
  99. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors
  100. Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity
  101. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG
  102. Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson’s Disease
  103. Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy
  104. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors
  105. Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21
  106. Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties
  107. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
  108. Design and Synthesis of Novel Cannabinoid Ligands Based on a 1,2,3- triazole Scaffold
  109. Cannabidiol administration after hypoxia–ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function
  110. A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
  111. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects
  112. Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
  113. Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB1 and CB2 Receptors
  114. Chromenopyrazoles: Non-psychoactive and Selective CB1Cannabinoid Agonists with Peripheral Antinociceptive Properties
  115. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases
  116. Fármacos cannabinoides para las enfermedades neurológicas: ¿qué hay detrás?
  117. Pharmacological Activation/Inhibition of the Cannabinoid System Affects Alcohol Withdrawal-Induced Neuronal Hypersensitivity to Excitotoxic Insults
  118. Prospects for cannabinoid therapies in basal ganglia disorders
  119. Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's disease
  120. Pharmacological Targeting of the Transcription Factor Nrf2 at the Basal Ganglia Provides Disease Modifying Therapy for Experimental Parkinsonism
  121. Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease
  122. Reply: Reliability of immunolabelling in the determination of Huntington's disease neuropathy
  123. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease
  124. A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice
  125. Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
  126. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain
  127. The endocannabinoid system as a target for the treatment of neuronal damage
  128. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors
  129. Cannabinoids and Parkinsons Disease
  130. Cannabinoids, multiple sclerosis and neuroprotection
  131. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
  132. Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration
  133. The endocannabinoid system as a target for the treatment of motor dysfunction
  134. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas
  135. The endocannabinoid system in neuropathological states
  136. Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease
  137. Cannabinoid signaling system
  138. The Endocannabinoid System in Huntingtons Disease
  139. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats
  140. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats
  141. Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance
  142. Role of CB2 receptors in neuroprotective effects of cannabinoids
  143. Cannabinoid CB1 Receptors Are Expressed by Parietal Cells of the Human Gastric Mucosa
  144. Cannabinoids and Neuroprotection in Motor-Related Disorders
  145. Preface: Cannabinoids as New Tools for the Treatment of Neurological Disorders
  146. Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acidin vivoby mechanisms independent of the activation of cannabinoid, vanilloid TRPV1and adenosine A2Areceptors
  147. Cannabinoids and Neuroprotection in Basal Ganglia Disorders
  148. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol
  149. The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain
  150. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties
  151. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions
  152. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
  153. An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments
  154. Effects of inhibition of fatty acid amide hydrolase vs. the anandamide membrane transporter on TRPV1‐mediated calcium responses in adult DRG neurons; the role of CB1 receptors
  155. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice
  156. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice
  157. Acyl‐based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations
  158. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease
  159. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders
  160. Chronic Δ9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex
  161. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis
  162. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels
  163. Therapeutic Potential of the Endocannabinoid System in the Brain
  164. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease
  165. Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice
  166. Cannabinoid tolerance and dependence: A review of studies in laboratory animals
  167. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease
  168. Changes in endocannabinoid contents in reward‐related brain regions of alcohol‐exposed rats, and their possible relevance to alcohol relapse
  169. Effects of Neonatal Exposure to Methamphetamine: Catecholamine Levels in Brain Areas of the Developing Rat
  170. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo
  171. Involvement of the Endocannabinoid System in Motor Disorders
  172. Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal Δ9-tetrahydrocannabinol exposure
  173. Behavioral and molecular changes elicited by acute administration of SR141716 to Δ9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence
  174. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence
  175. Transthyretin is involved in depression‐like behaviour and exploratory activity
  176. Cannabinoids and gene expression during brain development
  177. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake
  178. Prenatal Cannabinoid Exposure Down- Regulates Glutamate Transporter Expressions (GLAST and EAAC1) in the Rat Cerebellum
  179. Prenatal cannabinoid exposure and gene expression for neural adhesion molecule L1 in the fetal rat brain
  180. The Endocannabinoid System and Huntingtons Disease
  181. Effects of perinatal exposure to Δ9-tetrahydrocannabinol on operant morphine-reinforced behavior
  182. Region‐dependent changes in endocannabinoid transmission in the brain of morphine‐dependent rats
  183. Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate
  184. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors
  185. Design, Synthesis, and Biological Evaluation of New Inhibitors of the Endocannabinoid Uptake:  Comparison with Effects on Fatty Acid Amidohydrolase
  186. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease
  187. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine
  188. The endogenous cannabinoid system and the basal ganglia
  189. Erratum to “The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats” [Life Sciences 70(12) (2002) 1407-1414]
  190. PREFACE
  191. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide
  192. Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA‐induced excitotoxicity
  193. Endocannabinoid Transporter Inhibitors
  194. Prenatal Exposure to Methamphetamine in the Rat
  195. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels
  196. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington’s disease
  197. Endocannabinoids and basal ganglia functionality
  198. The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats
  199. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
  200. Exposure to cannabinoids in the development of endogenous cannabinoid system
  201. Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Δ-tetrahydrocannabinol
  202. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington’s disease
  203. Reduced Glial Fibrillary Acidic Protein and Glutamine Synthetase Expression in Astrocytes and Bergmann Glial Cells in the Rat Cerebellum Caused by Δ<sup>9</sup>-Tetrahydrocannabinol Administration during Development
  204. Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets
  205. Design, Synthesis and Biological Evaluation of Novel Arachidonic Acid Derivatives as Highly Potent and Selective Endocannabinoid Transporter Inhibitors
  206. Effects of cannabinoids on adrenaline release from adrenal medullary cells
  207. Anandamide, but not 2‐arachidonoylglycerol, accumulates during in vivo neurodegeneration
  208. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease
  209. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis
  210. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues
  211. Decreased Cannabinoid CB1 Receptor mRNA Levels and Immunoreactivity in Pituitary Tumors Induced by Prolonged Exposure to Estrogens
  212. Neonatal Methamphetamine in the Rat: Evidence for Gender‐specific Differences upon Tyrosine Hydroxylase Enzyme in the Dopaminergic Nigrostriatal System
  213. Uso de los cannabinoides a través de la historia
  214. Sistema cannabinoide endógeno: ligandos y receptores acoplados a mecanismos de transducción de señales
  215. Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9‐Tetrahydrocannabinol‐Tolerant Rats
  216. Sex Steroid Influence on Cannabinoid CB1 Receptor mRNA and Endocannabinoid Levels in the Anterior Pituitary Gland
  217. Activational role of cannabinoids on movement
  218. Prenatal Δ9-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences
  219. Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme
  220. Neuronal and Astroglial Response to Pre- and Perinatal Exposure to Delta-9-Tetra- Hydrocannabinol in the Rat Substantia nigra
  221. The endogenous cannabinoid system and brain development
  222. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen
  223. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period
  224. Pharmacological and biochemical interactions between opioids and cannabinoids
  225. Role of endocannabinoids in brain development
  226. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPγS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide
  227. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to Δ9-tetrahydrocannabinol
  228. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide
  229. Perinatal Δ9-Tetrahydrocannabinol Exposure Augmented the Magnitude of Motor Inhibition Caused by GABAB, but not GABAA, Receptor Agonists in Adult Rats
  230. Time-dependent differences of repeated administration with Δ9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by μ-opioid and CB1-cannabinoid receptors in the caudate–putamen
  231. Identification of Endocannabinoids and Cannabinoid CB<sub>1</sub> Receptor mRNA in the Pituitary Gland